Intraabdominal and retroperitoneal soft-tissue sarcomas - Surgical treatment and outcomes
(2022) In Surgical Oncology 42. p.1-7- Abstract
BACKGROUND: Intraabdominal and retroperitoneal sarcomas (IaRS) are malignant connective tissue tumors. Surgical resection is often the only curative treatment. The primary objective was to report the mid-term outcomes following contemporary treatment protocols and identify prognostic factors.
METHODS: A retrospective review of consecutive patients (n = 107) with IaRS treated at single center from 2013 until 2018 was conducted. Histological diagnosis, tumor grade, perioperative complications, mortality, and long-time survival were registered and retrieved from patient records. Primary and recurrent tumors were analyzed separately.
RESULTS: A total of 107 patients were identified. Median follow-up time was 3.5 years.... (More)
BACKGROUND: Intraabdominal and retroperitoneal sarcomas (IaRS) are malignant connective tissue tumors. Surgical resection is often the only curative treatment. The primary objective was to report the mid-term outcomes following contemporary treatment protocols and identify prognostic factors.
METHODS: A retrospective review of consecutive patients (n = 107) with IaRS treated at single center from 2013 until 2018 was conducted. Histological diagnosis, tumor grade, perioperative complications, mortality, and long-time survival were registered and retrieved from patient records. Primary and recurrent tumors were analyzed separately.
RESULTS: A total of 107 patients were identified. Median follow-up time was 3.5 years. Thirty-day mortality was 3.4% and 90-day mortality was 5.6% for all tumors. The major complication rate was 18%. The 5-year estimated survival for primary and recurrent tumors was 55.4% and 48.4%, respectively. Multifocal disease was evident in 32% of the patient cohort, and 58% of patients in the recurrent group. Multivariate analysis for survival revealed a hazard ratio (HR) of 3.1 (95% CI 1.68-8.41) for multifocality, HR 2.9 (95% CI 1.28-6.98) for Clavien-Dindo grade, HR 2.3 (95% CI 1.21-4.31) for tumor grades 2 or 3, and HR 1.002 (95% CI 1.001-1.004) for surgical margins.
CONCLUSIONS: Our study found overall acceptable morbidity and mortality, and identified prognostic markers for overall survival. Recurrent tumors were not associated with worse survival. Multifocality is associated with a worse overall survival. The prognostic factors identified were; tumor grade, multifocality, intralesional margins and postoperative complications.
(Less)
- author
- Tranberg, Anne ; Nielsen, Maja Kjer ; Sørensen, Flemming Brandt ; Thygesen, Knud ; Verwaal, Victor Jilbert LU ; Sørensen, Mette Møller ; Christensen, Henrik Kidmose and Funder, Jonas Amstrup
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- in
- Surgical Oncology
- volume
- 42
- article number
- 101781
- pages
- 1 - 7
- publisher
- Elsevier
- external identifiers
-
- pmid:35643015
- scopus:85130567795
- ISSN
- 0960-7404
- DOI
- 10.1016/j.suronc.2022.101781
- language
- English
- LU publication?
- no
- additional info
- Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
- id
- 7f1c9ce1-fe17-4fe0-bb70-bae87463a178
- date added to LUP
- 2022-06-02 20:05:31
- date last changed
- 2024-06-27 19:07:11
@article{7f1c9ce1-fe17-4fe0-bb70-bae87463a178,
abstract = {{<p>BACKGROUND: Intraabdominal and retroperitoneal sarcomas (IaRS) are malignant connective tissue tumors. Surgical resection is often the only curative treatment. The primary objective was to report the mid-term outcomes following contemporary treatment protocols and identify prognostic factors.</p><p>METHODS: A retrospective review of consecutive patients (n = 107) with IaRS treated at single center from 2013 until 2018 was conducted. Histological diagnosis, tumor grade, perioperative complications, mortality, and long-time survival were registered and retrieved from patient records. Primary and recurrent tumors were analyzed separately.</p><p>RESULTS: A total of 107 patients were identified. Median follow-up time was 3.5 years. Thirty-day mortality was 3.4% and 90-day mortality was 5.6% for all tumors. The major complication rate was 18%. The 5-year estimated survival for primary and recurrent tumors was 55.4% and 48.4%, respectively. Multifocal disease was evident in 32% of the patient cohort, and 58% of patients in the recurrent group. Multivariate analysis for survival revealed a hazard ratio (HR) of 3.1 (95% CI 1.68-8.41) for multifocality, HR 2.9 (95% CI 1.28-6.98) for Clavien-Dindo grade, HR 2.3 (95% CI 1.21-4.31) for tumor grades 2 or 3, and HR 1.002 (95% CI 1.001-1.004) for surgical margins.</p><p>CONCLUSIONS: Our study found overall acceptable morbidity and mortality, and identified prognostic markers for overall survival. Recurrent tumors were not associated with worse survival. Multifocality is associated with a worse overall survival. The prognostic factors identified were; tumor grade, multifocality, intralesional margins and postoperative complications.</p>}},
author = {{Tranberg, Anne and Nielsen, Maja Kjer and Sørensen, Flemming Brandt and Thygesen, Knud and Verwaal, Victor Jilbert and Sørensen, Mette Møller and Christensen, Henrik Kidmose and Funder, Jonas Amstrup}},
issn = {{0960-7404}},
language = {{eng}},
pages = {{1--7}},
publisher = {{Elsevier}},
series = {{Surgical Oncology}},
title = {{Intraabdominal and retroperitoneal soft-tissue sarcomas - Surgical treatment and outcomes}},
url = {{http://dx.doi.org/10.1016/j.suronc.2022.101781}},
doi = {{10.1016/j.suronc.2022.101781}},
volume = {{42}},
year = {{2022}},
}